Health Economics›Multiple myeloma›First-line therapy quadruplets

First-line therapy quadruplets

Multiple myeloma · 11 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Dara-KRd Variant #01	—	R 737 566	28d	—	—	~8	~R 2 180 742 indirect	—
Dara-VMP Variant #01	—	R 694 265	42d	—	83.0 mo	9	R 1 921 705 PFS proxy	3
Dara-VTD Variant #01	—	R 521 726	28d	—	—	4	R 1 073 658 PFS proxy	1
Dara-RVd Variant #01	—	R 263 616	21d	—	—	~4	~R 1 054 466 indirect	—
KRdc Variant #01	—	R 195 326	28d	—	—	5	R 526 700 PFS proxy	2
CYKLONE Variant #01	—	R 167 713	28d	—	—	~12	~R 1 286 619 indirect	—
Isa-RVd Variant #01 Partial	—	R 22 260	42d	—	—	3	R 66 779 PFS proxy	2
Dara-VMP (SC daratumumab) Variant #01 Partial	—	R 20 393	42d	—	—	~9	~R 68 583 indirect	—
VMPT Variant #01	—	R 12 072	42d	—	—	6	R 72 429 PFS proxy	2
Dara-RVd (SC daratumumab) Variant #01 Partial	—	R 11 086	28d	—	—	8	R 88 691 PFS proxy	1
RVDC Variant #01	—	R 10 903	21d	—	—	~8	~R 87 224 indirect	—

11 of 11 regimens shown